Pharmacologic prophylaxis regimens for acute graft-versus-host disease: Past, present and future

Ron Ram*, Rainer Storb

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Acute graft-versus-host disease (GVHD) has compromised and continues to compromise the benefits associated with allogeneic hematopoietic cell transplant to cure malignant and non-malignant diseases. Pharmacologic interventions to prevent GVHD have emerged as a major objective of research in the immunology and transplant fields. A better understanding of the pathobiology behind the GVHD process has led the way to novel approaches and medications. Here we review the present arsenal of medications used to prevent GVHD, focusing on past experience and the current evidence, and discuss future potential targets.

Original languageEnglish
Pages (from-to)1591-1601
Number of pages11
JournalLeukemia and Lymphoma
Volume54
Issue number8
DOIs
StatePublished - Aug 2013
Externally publishedYes

Funding

FundersFunder number
National Institutes of HealthCA 18029, CA 15704
National Cancer InstituteP01CA078902

    Keywords

    • Allogeneic transplant
    • GVHD
    • Prophylaxis

    Fingerprint

    Dive into the research topics of 'Pharmacologic prophylaxis regimens for acute graft-versus-host disease: Past, present and future'. Together they form a unique fingerprint.

    Cite this